Yu Chen
Director/Board Member at Genor Biopharma Co., Ltd.
Profile
Yu Chen is currently a Director at Genor Biopharma Co., Ltd.
and PharmaLegacy Laboratories (Shanghai) Co., Ltd.
Previously, he held positions as a Director at Suzhou NanoMicro Technology Co. Ltd., GemPharmatech Co., Ltd., Genor Biopharma Holdings Ltd., and Zhaoke Ophthalmology Ltd.
He also worked as an Associate at Citigroup Global Markets Asia Ltd.
and as a Senior Manager-Investment at Shanghai Panxin Equity Investment Management Co. Ltd.
Mr. Chen received his graduate degree from Stanford University in 2008, his graduate degree from Yale University in 2005, and his undergraduate degree from The Hong Kong University of Science & Technology in 2003.
Yu Chen active positions
Companies | Position | Start |
---|---|---|
Genor Biopharma Co., Ltd.
Genor Biopharma Co., Ltd. BiotechnologyHealth Technology Genor Biopharma Co., Ltd. engages in the manufacture and development of antibodies and related biological products. Its business scope includes research and development of monoclonal antibodies and biological products; research and development of instruments, equipment and reagents related to monoclonal antibodies and biological products; and wholesale, import and export of instruments, mechanical equipment, pharmaceutical equipment, and pharmaceutical intermediates. The company was founded on December 4, 2007 and is headquartered in Shanghai, China. | Director/Board Member | - |
PharmaLegacy Laboratories (Shanghai) Co., Ltd.
PharmaLegacy Laboratories (Shanghai) Co., Ltd. Miscellaneous Commercial ServicesCommercial Services PharmaLegacy Laboratories (Shanghai) Co., Ltd. engages in the provision of pharmacodynamics, pharmacokinetics, non-GLP toxicology, in vitro immunology, and three types of medical device evaluation services in line with international standards. It provides drug research & development preclinical research services such as pharmacodynamic research evaluation and pharmacokinetic research evaluation; device research & development preclinical research services such as preclinical effectiveness and safety evaluation of innovative medical devices; and experimental mice. The company was founded on March 7, 2008 and is headquartered in Shanghai, China. | Director/Board Member | 2021-06-30 |
Former positions of Yu Chen
Companies | Position | End |
---|---|---|
ZHAOKE OPHTHALMOLOGY LIMITED | Director/Board Member | 2024-04-07 |
GENOR BIOPHARMA HOLDINGS LIMITED | Director/Board Member | 2024-01-01 |
GEMPHARMATECH CO., LTD. | Director/Board Member | 2023-04-03 |
SUZHOU NANOMICRO TECHNOLOGY CO., LTD. | Director/Board Member | 2022-03-29 |
Shanghai Panxin Equity Investment Management Co. Ltd. | Chief Investment Officer | 2015-06-30 |
Training of Yu Chen
The Hong Kong University of Science & Technology | Undergraduate Degree |
Yale University | Graduate Degree |
Stanford University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 4 |
---|---|
GENOR BIOPHARMA HOLDINGS LIMITED | Health Technology |
ZHAOKE OPHTHALMOLOGY LIMITED | Health Technology |
SUZHOU NANOMICRO TECHNOLOGY CO., LTD. | Commercial Services |
GEMPHARMATECH CO., LTD. | Health Technology |
Private companies | 4 |
---|---|
Citigroup Global Markets Asia Ltd.
Citigroup Global Markets Asia Ltd. Investment Banks/BrokersFinance Citigroup Global Markets Asia Ltd. (CGMA) is a securities brokerage firm headquartered Hong Kong. They are a subsidiary of Citigroup Global Markets Hong Kong Holdings Ltd., ultimately owned by Citigroup, Inc. (NYSE: C) in the US. Formerly known as Citi Smith Barney, the firm was reorganized in 2008 when Citigroup combined their brokerage and private banking businesses. CGMA offers stock trading services to various institutional investors. | Finance |
Shanghai Panxin Equity Investment Management Co. Ltd. | |
Genor Biopharma Co., Ltd.
Genor Biopharma Co., Ltd. BiotechnologyHealth Technology Genor Biopharma Co., Ltd. engages in the manufacture and development of antibodies and related biological products. Its business scope includes research and development of monoclonal antibodies and biological products; research and development of instruments, equipment and reagents related to monoclonal antibodies and biological products; and wholesale, import and export of instruments, mechanical equipment, pharmaceutical equipment, and pharmaceutical intermediates. The company was founded on December 4, 2007 and is headquartered in Shanghai, China. | Health Technology |
PharmaLegacy Laboratories (Shanghai) Co., Ltd.
PharmaLegacy Laboratories (Shanghai) Co., Ltd. Miscellaneous Commercial ServicesCommercial Services PharmaLegacy Laboratories (Shanghai) Co., Ltd. engages in the provision of pharmacodynamics, pharmacokinetics, non-GLP toxicology, in vitro immunology, and three types of medical device evaluation services in line with international standards. It provides drug research & development preclinical research services such as pharmacodynamic research evaluation and pharmacokinetic research evaluation; device research & development preclinical research services such as preclinical effectiveness and safety evaluation of innovative medical devices; and experimental mice. The company was founded on March 7, 2008 and is headquartered in Shanghai, China. | Commercial Services |
- Stock Market
- Insiders
- Yu Chen